STING1 and neoplasm: A panel of innovative approaches, such as a hydrogel enclosing GM-CSF or FLT3L and CpG, PEG-lipid nanodiscs enclosing STING-activating cyclic dinucleotides (CDNs), and a bridging-lipid nanoparticle (B-LNP) conjugating STING agonist and anti-CD47/PD-L1 were recently developed to increase tumor penetration, disrupt phagocytosis checkpoints and induce long-lasting antitumor immunity [120–122].